Moleculin Biotech

Moleculin Biotech FCF per Share

The Free Cash Flow per Share of Moleculin Biotech (MBRX) as of Nov 3, 2026 is -7.11 USD. In the previous year, Free Cash Flow per Share was -176.59 USD — a change of -95.98% (higher).

FCF per Share

-7.11USD

YoY

-95.98%

Last updated:

Free Cash Flow per Share of Moleculin Biotech is 2025 -7.11 USD. Free Cash Flow per Share of Moleculin Biotech was 2024 -176.59 USD. It decreases by -95.98% higher compared to the previous year.

The Moleculin Biotech FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2018
-1,017.74 USD
Jan 1, 2019
-849.75 USD
Jan 1, 2020
-589.19 USD
Jan 1, 2021
-248.95 USD
Jan 1, 2022
-363.12 USD
Jan 1, 2023
-302.43 USD
Jan 1, 2024
-176.59 USD
Jan 1, 2025
-7.11 USD
The Moleculin Biotech FCF per Share history
YEARFCF per ShareYoY
-7.11USD-95.98%
-176.59USD-41.61%
-302.43USD-16.71%
-363.12USD+45.86%
-248.95USD-57.75%
-589.19USD-30.66%
-849.75USD-16.51%
-1,017.74USD+31.51%
-773.89USD+29,720.41%
-2.60USD-98.89%
-233.95USD+8.84%
-214.95USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Moleculin Biotech Stock analysis

What does Moleculin Biotech do? Moleculin Biotech Inc is a clinical-stage pharmaceutical company focused on developing treatments for cancers. Its drug candidates include Annamycin for relapsed or refractory acute myeloid leukemia and lung metastases, WP1066 as a p-STAT3 inhibitor targeting brain tumors and pancreatic cancer, WP1220 for cutaneous T-cell lymphoma, and WP1732, WP1122, and WP1234 for AML, pancreatic cancer, and brain tumors through glycolysis inhibition. The company generates revenue through the development and potential commercialization of these clinical-stage drugs, targeting oncology specialists and healthcare providers in the pharmaceutical sector. Moleculin's products are positioned for late-stage clinical trials with potential partnerships for drug development and commercialization. The company's primary revenue stream comes from the progression of its drug candidates through clinical trials, with potential future sales once regulatory approvals are secured. Annamycin, WP1066, WP1220, WP1732, WP1122, and WP1234 are the key products under development, each targeting specific cancer types such as AML, brain tumors, pancreatic cancer, and cutaneous T-cell lymphoma. Healthcare providers and oncology specialists are the primary buyers of these future products, as they will prescribe them to patients in clinical settings. Moleculin Biotech's business model relies on advancing its pipeline of oncology-focused drug candidates through clinical trials, with the goal of securing partnerships or licensing agreements with larger pharmaceutical companies for further development and commercialization. The company's products are designed to address unmet medical needs in cancer treatment, targeting segments including hematological malignancies, solid tumors, and skin cancers. Revenue is anticipated once drugs receive regulatory approval and enter the market, with current focus on completing clinical trials to demonstrate efficacy and safety. Moleculin Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Moleculin Biotech stock

Free Cash Flow per Share of Moleculin Biotech is -7.11 USD in 2025.

Free Cash Flow per Share of Moleculin Biotech changed from -176.59 USD to -7.11 USD, representing a -95.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Moleculin Biotech since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Moleculin Biotech

All Key Metrics — Moleculin Biotech